Investigation of Pectoralis Muscle Strength in Elderly With Interstitial Lung Disease
16 maart 2021 bijgewerkt door: Habibedurdu
The Effect of Pectoralis Muscle Strength on Pulmonary Function in Elderly With Interstitial Lung Disease
Interstitial lung disease (ILD) is a restrictive lung disease characterized by impaired lung function, exercise limitation and skeletal muscle dysfunction.
There is limited data on skeletal muscle function in ILD, most of which are focused on the lower limb muscles.
The aim of this study were to evaluated the change of pectoralis muscle strength and relationship of pulmonary function with pectoralis muscle strength.
Studie Overzicht
Toestand
Voltooid
Interventie / Behandeling
Gedetailleerde beschrijving
This study consisted of intervention and control groups.
Thirty one patients with ILD were included in the patient's group and 37 healthy volunteers in the control group.
All participants were selected from the geriatric population.
Demographic and cardiopulmonary physiotherapy assessment of all participants were performed.
Lung function test, maximal inspiratory and expiratory pressure and pectoralis muscle strength were measured in participants of both groups.
All measurements were performed once.
Studietype
Observationeel
Inschrijving (Werkelijk)
68
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studie Locaties
-
-
-
Giresun, Kalkoen
- Giresun University
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
65 jaar tot 85 jaar (Oudere volwassene)
Accepteert gezonde vrijwilligers
Nee
Geslachten die in aanmerking komen voor studie
Allemaal
Bemonsteringsmethode
Niet-waarschijnlijkheidssteekproef
Studie Bevolking
The patient's group was selected from among the patients who applied to Süreyyapaşa Chest Diseases and Thoracic Surgery Training and Research Hospital.
The control group was selected among volunteers invited from the local community.
Beschrijving
Inclusion Criteria:
- Diagnosed with ILD by a multidisciplinary team according to the 2011 ATS/ERS guidelines for ILD
- Aged 65-85
Exclusion Criteria:
- Uncontrolled/active cardiovascular, metabolic, systemic or cancerous disease
- Significant orthopedic, neurologic or musculoskeletal comorbidity that limited functional independence
- No being able to cooperate
- Refuse to participate in the current study
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: Case-control
- Tijdsperspectieven: Prospectief
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
Patient's group
geriatric patients with interstitial lung disease
|
In both groups, forced vital capacity (FVC), forced expiratory volume in one second (FEV1) and FEV1 / FVC ratio were measured with portable spirometer according to the guidelines of the American Thoracic Society (ATS) and the European Respiratory Society (ERS).
Maximal inspiratory (MIP) and expiratory pressure (MEP) were evaluated with mouth pressure device as per ATS/ERS guidelines.
Sensation of dyspnea was assessed with Modified medical council research scale.
Pectoralis muscle strength were measured isometrically using with digital hand held dynamometer.
|
|
Control group
healthy volunteers selected from the geriatric population
|
In both groups, forced vital capacity (FVC), forced expiratory volume in one second (FEV1) and FEV1 / FVC ratio were measured with portable spirometer according to the guidelines of the American Thoracic Society (ATS) and the European Respiratory Society (ERS).
Maximal inspiratory (MIP) and expiratory pressure (MEP) were evaluated with mouth pressure device as per ATS/ERS guidelines.
Sensation of dyspnea was assessed with Modified medical council research scale.
Pectoralis muscle strength were measured isometrically using with digital hand held dynamometer.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Pectoralis muscle strength test
Tijdsspanne: 15 minute
|
The pectoralis muscle strength were measured with handheld dynamometer in supine position.
The shoulder joint of participant was positioned at 90º abducted and at 0º internal/external rotation and the elbow joint was flexed at 90º.
The other shoulder joint was fixed by the physiotherapist.
While the participant performed isometrically horizontal adduction movement, the measurement was performed on the distal part of the upper arm and the contraction was sustained for at least 5 seconds by the participant.
The test was performed three times and with 60 seconds rest between tests.
The mean of the best value on both sides was recorded.
|
15 minute
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
FEV1
Tijdsspanne: 5 minute
|
FEV1 value was measured with portable spirometer according to ATS/ ERS guidelines for pulmonary function test.
Results of the measurements were recorded as percentanges of predicted values.
|
5 minute
|
|
FVC
Tijdsspanne: 5 minute
|
FVC value was measured with portable spirometer according to ATS/ ERS guidelines for pulmonary function test.
Results of the measurements were recorded as percentanges of predicted values.
|
5 minute
|
|
FEV1/FVC
Tijdsspanne: 5 minute
|
The ratio of FEV1/FVC was calculated by measuring device according to measured FEV1 and FVC values
|
5 minute
|
|
Respiratory muscle strength test
Tijdsspanne: 15 minute
|
Maximal mouth pressures were measured to evaluate respiratory muscle strength.
The test was performed with mouth pressure device in sitting position.
Participants breathed through a flanged mouthpiece inside the lips at near residual volume for the MIP value and near total lung capacity for MEP value .
The maximum effort was sustained for at least one second.
The test was repeated at least 3 times until no more than 10% difference was present between highest and previous measurements .
The higest value and percentage value of predicted highest value were recorded
|
15 minute
|
|
Dyspnea assessment
Tijdsspanne: 3 minute
|
Modified Medical Council Research Dyspnea scale were used to assess sensation of dyspnea
|
3 minute
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Onderzoekers
- Hoofdonderzoeker: Habibe DURDU, MSc, Giresun University
Publicaties en nuttige links
De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.
Algemene publicaties
- Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Muller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schunemann HJ; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824. doi: 10.1164/rccm.2009-040GL.
- Hirano M, Katoh M, Kawaguchi S, Uemura T. Intrarater reliabilities of shoulder joint horizontal adductor muscle strength measurements using a handheld dynamometer for geriatric and stroke patients. J Phys Ther Sci. 2016 Jan;28(1):51-5. doi: 10.1589/jpts.28.51. Epub 2016 Jan 30.
- Panagiotou M, Polychronopoulos V, Strange C. Respiratory and lower limb muscle function in interstitial lung disease. Chron Respir Dis. 2016 May;13(2):162-72. doi: 10.1177/1479972315626014. Epub 2016 Jan 14.
- Hanada M, Sakamoto N, Ishimatsu Y, Kakugawa T, Obase Y, Kozu R, Senjyu H, Izumikawa K, Mukae H, Kohno S. Effect of long-term treatment with corticosteroids on skeletal muscle strength, functional exercise capacity and health status in patients with interstitial lung disease. Respirology. 2016 Aug;21(6):1088-93. doi: 10.1111/resp.12807. Epub 2016 May 13.
- Durdu H, Yurdalan SU, Ozmen I. Clinical significance of pectoralis muscle strength in elderly patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2022;39(1):e2022009. doi: 10.36141/svdld.v39i1.12094. Epub 2022 Mar 31.
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Werkelijk)
23 januari 2017
Primaire voltooiing (Werkelijk)
23 juni 2017
Studie voltooiing (Werkelijk)
23 juni 2017
Studieregistratiedata
Eerst ingediend
13 maart 2021
Eerst ingediend dat voldeed aan de QC-criteria
16 maart 2021
Eerst geplaatst (Werkelijk)
17 maart 2021
Updates van studierecords
Laatste update geplaatst (Werkelijk)
17 maart 2021
Laatste update ingediend die voldeed aan QC-criteria
16 maart 2021
Laatst geverifieerd
1 maart 2021
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- Pectoralismajor
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Nee
Beschrijving IPD-plan
The data sets collected and analyzed during this study could be provided from corresponding author upon reasonable request
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Nee
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Nee
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .